Juventus eye Ipswich striker Delap - Sunday's gossipIn a striking development, global shares received a boost amid a significant rally in U.S. tech stocks and prospects of lower interest rates. Wednesday saw Wall Street's major indexes climb to record highs, despite political upheaval in both South Korea and France. Tech heavyweights Salesforce and Marvell Technology posted impressive third-quarter results, contributing to a surge in both the Nasdaq Composite and S&P 500. Nevertheless, UnitedHealth's gains were overshadowed by the tragic fatal shooting of its insurance unit CEO in New York. Political tensions in South Korea and France added layers of uncertainty. South Korea's KOSPI index plummeted as the nation grappled with calls for President Yoon Suk Yeol's resignation. In France, a no-confidence vote further strained the fragile government coalition led by Prime Minister Michel Barnier. (With inputs from agencies.)The first-generation Kindle Scribe in a certified refurbished state is now on sale for a flat . This makes the E Ink tablet to be priced at $233.99 against a list price of $309.99. The tablet offers 16 GB of storage and is accompanied by a Premium Pen. Interestingly, the Amazon listing describes the tablet as one with a 10.2-inch 300 PPI Paperwhite display. That could be to highlight its monochrome nature or it having the same 300 PPI display which is the same that the Kindle Paperwhite also offers. The Kindle Scribe is the largest of all Kindle devices thanks to the 10.2-inch E Ink display it comes with. It also comes with the largest battery among all Kindle devices. Amazon recently launched the new 2024 Kindle Scribe which comes with several enhancements over the first-gen model. However, the good thing here is that Amazon has stated all of the new AI-enabled features of the 2024 Kindle Scribe will be made available to the Kindle Scribe as well. That would be via a software update that is expected to arrive by the end of this year or early next. Among the new features that are touted to make their way to the first-generation Kindle Scribe is Active Canvas. This will allow users to jot down notes right on a book itself. So far, users could only take notes on a pop-up window and not on the book itself. With Active Canvas, you can start taking notes at the top of the display in a book. This itself acts as the trigger for a box to appear underneath your writings. Then there is going to be the Extended Margin feature, something that will let users to write down notes in the on-screen side panel. users will also have the option to show or hide the notes. Apart from these, the Scribe will also have several generative AI features that will let it perform various tasks with ease. Those can be creating a summary of a given article, writing a fresh article based on a given set of guidelines. Amazon meanwhile has stated all of its certified refurbished products go through a stringent quality control procedure. Such devices are subjected to a series of tests and are updated to run the latest software version. The battery too is tested and charged to a given level. With a keen interest in tech, I make it a point to keep myself updated on the latest developments in technology and gadgets. That includes smartphones or tablet devices but stretches to even AI and self-driven automobiles, the latter being my latest fad. Besides writing, I like watching videos, reading, listening to music, or experimenting with different recipes. The motion picture is another aspect that interests me a lot, and I'll likely make a film sometime in the future.Ireland's two large centre-right parties look on course to be returned to power but they will likely need at least one smaller partner to secure a majority, raising questions about the stability of the next government. or signup to continue reading That could leave the parties facing prolonged negotiations or an unstable coalition ahead of the inauguration of US President-elect Donald Trump, whose pledge to slash corporate tax and impose tariffs poses a threat to the Irish economy. After voters went to the polls on Friday, governing parties Fine Gael and Fianna Fail were on 20.5 per cent and 21.9 per cent of first-preference votes respectively, according to a tally by Virgin Media News with left-wing Sinn Fein on 19.1 per cent. With the two centre-right parties ruling out a deal with Sinn Fein, the main question was how close to the 88 seats needed for a majority the pair can get - and whether they would need one or two more coalition parties to get over the line. "Clearly there is a route there to government," Fianna Fail's leader and deputy prime minister, Micheal Martin, told state broadcaster RTE when asked about a deal with Fine Gael and another party. "But a lot will depend ... on how many seats the respective parties get." It was "far too early" to discuss possible coalition partners or whether he might be the next prime minister, he said. Fianna Fail could get as many as 48 seats and Fine Gael could take 39, leaving them on the cusp of 88 seats, former Trinity College Dublin political science professor Michael Gallagher told RTE, citing vote tallies. The most obvious candidates for a coalition partner would be centre-left parties Labour and the Social Democrats, who Gallagher said could take eight seats each. But if those numbers are lower when votes are counted under Ireland's complex system of proportional representation, four parties could be needed to form a government, making it much more fragile. A clear outline of final seat numbers was not expected to emerge until Sunday. The current junior coalition party, the Greens, were in danger of losing all 12 of their seats, party leader Roderic O'Gorman said. Prime Minister Simon Harris called the election on the heels of a 10.5 billion euro ($A17 billion) giveaway budget that began to put money into voters' pockets during the campaign, largesse made possible by billions of euros of foreign multinational corporate tax revenues. However, a campaign full of missteps for his Fine Gael party, culminating last weekend in a viral clip of Harris walking away from an exasperated care worker, cost them their pre-election lead. The government parties also faced widespread frustration during the campaign at their inability to turn the healthiest public finances in Europe into better public services. Sinn Fein, the former political wing of the Irish Republican Army, appeared on course to lead the next government a year ago but suffered a slide in support from 30 per cent to 35 per cent, in part due to anger among its working-class base at relatively liberal immigration policies. Fine Gael and Fianna Fail, former rivals that have between them led every government since the foundation of the state almost a century ago, agreed to share the role of prime minister during the last government, switching roles halfway through the five-year term. DAILY Today's top stories curated by our news team. WEEKDAYS Grab a quick bite of today's latest news from around the region and the nation. WEEKLY The latest news, results & expert analysis. WEEKDAYS Catch up on the news of the day and unwind with great reading for your evening. WEEKLY Get the editor's insights: what's happening & why it matters. WEEKLY Love footy? We've got all the action covered. WEEKLY Every Saturday and Tuesday, explore destinations deals, tips & travel writing to transport you around the globe. WEEKLY Going out or staying in? Find out what's on. WEEKDAYS Sharp. Close to the ground. Digging deep. Your weekday morning newsletter on national affairs, politics and more. TWICE WEEKLY Your essential national news digest: all the big issues on Wednesday and great reading every Saturday. WEEKLY Get news, reviews and expert insights every Thursday from CarExpert, ACM's exclusive motoring partner. TWICE WEEKLY Get real, Australia! Let the ACM network's editors and journalists bring you news and views from all over. AS IT HAPPENS Be the first to know when news breaks. DAILY Your digital replica of Today's Paper. Ready to read from 5am! DAILY Test your skills with interactive crosswords, sudoku & trivia. Fresh daily! Advertisement Advertisement
Stock market today: Tech stocks and AI pull Wall Street to more records
Following a number of deaths due to this phenomenon, KAZEEM BIRIOWO examines how antimicrobial resistance has become an increasing concern in Nigeria, and how the Nigerian government, working with global health organisations, can reduce the scourge. Antimicrobial resistance (AMR) is a global health threat that has been described as a “silent tsunami” by the World Health Organisation (WHO). AMR is when bacteria, viruses, fungi, and parasites change over time and no longer respond to medicines used to treat them. This makes infections harder to treat and increases the risk of disease spread, severe illness, disability, and death. AMR is a natural process, but human activity, such as the misuse and overuse of antimicrobials, accelerates its emergence and spread. Microorganisms that develop resistance to antimicrobials are sometimes called “superbugs”. AMR affects all countries, but Africa is likely to bear the heaviest burden. The burden of AMR is felt disproportionately in low- and middle-income countries, including Nigeria, where the healthcare system is already overburdened. AMR represents a global challenge as 4.95 million people who died in 2019 suffered from drug-resistant infections. AMR directly caused 1.27 million of those deaths and one in five of those deaths occurred among children under five years old. In the GBD region of Western Sub-Saharan Africa, Nigeria has the seventh highest age-standardised mortality across 19 countries Deadly effects of AMR There are several victims of AMR in Nigeria, some of whom are no longer alive. Those who Nigerian Tribune spoke with were comfortable with just their surnames being used. Mrs Adebayo, a 35-year-old mother of two, knows firsthand the devastating effects of AMR. Her seven-year-old son, Tunde, was diagnosed with pneumonia and was treated with antibiotics. However, the antibiotics proved ineffective and Tunde’s condition worsened. He was eventually diagnosed with a multidrug-resistant form of pneumonia which required more expensive antibiotics. “We were devastated when we found out that the antibiotics were not working,” Mrs Adebayo said. “We had to sell our belongings to afford the more expensive antibiotics. It was a very difficult time for us.” Similarly, Mr Okoro, a 42-year-old businessman, also has a personal experience with AMR. His 65-year-old mother was diagnosed with a urinary tract infection and was treated with antibiotics. However, the antibiotics were ineffective, and her condition worsened. She eventually died from complications related to the infection. “The death of my mother was a devastating blow to our family,” Mr Okoro said. “We were not aware of the risks associated with AMR and we did not know how to prevent it. We hope that our story can serve as a warning to others and encourage them to take action to prevent AMR.” Miss Chukwu, a 28-year-old nurse, has seen the devastating effects of AMR almost on a daily basis. She works in a hospital in Lagos, where she has seen many patients die from infections that were resistant to antibiotics. “It is heartbreaking to see patients die from infections that could have been treated with antibiotics,” Miss Chukwu said. “We need to do more to prevent AMR and ensure that antibiotics are used responsibly.” Causes and consequences of AMR in Nigeria According to the WHO, the causes of AMR in Nigeria are multifaceted and interconnected. Some of the key causes include misuse and overuse of antibiotics which are major drivers of AMR. In Nigeria, antibiotics are often prescribed inappropriately and patients often demand antibiotics for viral infections, which do not respond to antibiotics. Also lack of National Antibiotic Guidelines in Nigeria contributes to the misuse of antibiotics. Healthcare professionals often rely on personal experience and judgment when prescribing antibiotics rather than following evidence-based guidelines. General awareness and understanding of AMR in Nigeria is poor. Many healthcare professionals and the general public are not aware of the risks associated with AMR which contributes to the misuse and overuse of antibiotics. Inadequate infection control measures in Nigerian hospitals contribute to the spread of microbes, including resistant strains. Poor hygiene practices, inadequate use of personal protective equipment and lack of sterilisation of medical equipment are common in many Nigerian hospitals. The consequences of AMR in Nigeria are severe and far-reaching. Some of the key consequences include, increased morbidity and mortality. AMR poses a risk of increased morbidity and mortality, particularly in low- and middle-income countries like Nigeria. The economic burden of AMR is also substantial as a study published in the Journal of Pharmaceutical Policy and Practice estimated that the economic burden of AMR in Nigeria could be as high as $1.3 billion annually. According to the study, “AMR reduces the effectiveness of antibiotics, making it challenging to treat infections. This can lead to prolonged hospital stays, increased healthcare costs, and increased mortality. “AMR increases the risk of infections, particularly in vulnerable populations such as the elderly, young children, and people with compromised immune systems.” State of AMR in Nigeria Nigeria, with a population of over 200 million people, is faced with the burden of poverty and poor environmental conditions, such as lack of potable water and sanitation, and inadequate infection control. These factors are crucial in the spread of microbes, including resistant strains. According to the Institute for Health Metrics and Evaluation (IHME), University of Washington, Nigeria had an estimated 627,000 deaths attributable to AMR in 2019, which is the highest number of deaths in Africa. The IHME also estimated that the mortality rate due to AMR in Nigeria was 335.6 deaths per 100,000 population in 2019. Urgent need to tackle AMR Dr John Oladapo, a consultant microbiologist at the Lagos University Teaching Hospital (LUTH), emphasized the urgent need to address the growing burden of AMR in Nigeria. “AMR is a ticking time bomb in Nigeria,” Dr Oladapo said. “We need to take immediate action to address the root causes of AMR, including the misuse and overuse of antibiotics, poor infection control practices, and lack of awareness about AMR.” Dr Adebiwale Akintayo, a public health expert at the University of Ibadan, emphasized the need for a multifaceted approach to address AMR in Nigeria. “We need to adopt a comprehensive approach to address AMR in Nigeria,” Dr Akintayo said. “This includes improving infection control practices, promoting responsible use of antibiotics, and enhancing awareness and understanding of AMR among healthcare professionals and the general public.” Dr Eyitope Ogunbodede, a professor of microbiology at the Obafemi Awolowo University (OAU), emphasized the need for research and development of new antibiotics to address the growing problem of AMR. “We need to invest in research and development of new antibiotics to address the growing problem of AMR. “We also need to improve our surveillance systems to monitor the spread of AMR and develop effective strategies to prevent it,” he said. FG’s action plan Recently, the Federal Government launched the National Action Plan on Antimicrobial Resistance (AMR NAP-2.0). The Coordinating Minister of Health and Social Welfare, Professor Muhammad Ali Pate, said the launch of AMR NAP-2.0 came at a time when the global community, through platforms like the 2024 United Nations General Assembly (UNGA), had committed to renewed and urgent action against AMR. He said in 2017, Nigeria made significant strides by launching its first National Action Plan on AMR, adding “We recognised that a multisectoral, one health approach-integrating human, animal, and environmental health-was essential in confronting AMR.” The minister also disclosed that the Federal Government is committed to integrating genomic technologies into all aspects of the work, noting that a plan has been laid out to build capacity for genomic sequencing and surveillance, as well as improving response to emerging infections and advancing vaccine development. The Director General of the Nigeria Centre for Disease Control and Prevention (NCDC), Dr Jide Idris, said the second AMR National Action Plan is a comprehensive five-year strategy designed to combat antimicrobial resistance in Nigeria, adding that the NCDC leads the Antimicrobial Resistance Coordination Committee (AMRCC) to drive the implementation of the plan’s priority actions. Co- chair of the national AMR Technical Working Group, Professor Kabiru Junaid, said it will cost a total of $77.6 million to implement all the strategic objectives of the AMR National Action Plan. The Minister of Agriculture and Food Security, Sen. Abubakar Kyari, said his ministry is committed to the implementation of the activities of the action plan. The Minister of Environment, Mallam Balarabe Abbas Lawal, speaking through the Director, Department of Pollution Control and Environmental Health, Bahijjahtu Abubakar, said effective implementation of the plan will improve the country’s strategies in addressing AMR and strengthening surveillance in the environment sector, livestock and healthcare settings, while promoting sustainable standard practices that ensures food security, protection of the environment and human health. WHO’s role in supporting AMR efforts WHO has been a key technical partner in developing AMR NAP-2.0, providing guidance on global best practices and supporting the Federal Government in aligning its strategies with the Global Action Plan on AMR. To improve the national efforts to control the impact of AMR, the ministry launched the AMR NAP 2.0, which is a revision of the national action plan on AMR adopted in 2017. With the expiration of the AMR NAP-1.0 (2017-2022), an assessment of its implementation revealed key gaps and challenges, with only a 44 percent completion rate. The assessment highlighted weak involvement from sectors such as environment, plant, food, aquaculture, agriculture, and relevant human health sectors in the implementation of priority activities. Additionally, NAP-1.0 was not costed and lacked specific milestones and targets. In response, the Government of Nigeria, through the Federal Ministry of Health and NCDC, requested WHO’s support in developing NAP-2.0 (2024-2028) and providing strategic guidance for the AMR Coordination Committee to develop the plan based on the AMR Global Action Plan, WHO manual for NAP Development, WHO implementation handbook for NAPs on AMR, and the People-cantered approach to addressing antimicrobial resistance in human health. This story is produced for the Media-EIS Fellowship Programme, a collaborative partnership among the Nigeria Centre for Disease Control and Prevention(NCDC), the USAID-funded Breakthrough ACTION Nigeria and the African Field Epidemiology Network(AFENET) Get real-time news updates from Tribune Online! Follow us on WhatsApp for breaking news, exclusive stories and interviews, and much more. Join our WhatsApp Channel nowCRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Financial Highlights "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 Current Assets: Cash and cash equivalents $ 112 $ — Inventory 8,268,766 — Prepaid expenses 2,700,000 7,734,895 Total Current Assets 10,968,878 7,734,895 Other Assets: In-process research and development 73,400,000 40,000,000 Total Other Assets 73,400,000 40,000,000 Total Assets $ 84,368,878 $ 47,734,895 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,711,622 $ 1,289,045 License payable 28,400,000 — Accrued expenses — 259,071 Due to related party 588,806 19,499,119 Total Current Liabilities 32,700,429 21,047,235 Deferred tax liability 1,728,000 1,152,000 Note payable to related party 3,800,111 — Total Liabilities 38,228,540 22,199,235 Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding — — Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,155 6,750 Additional paid-in capital 85,411,771 43,658,750 Accumulated deficit (39,278,587) (18,129,840) Total Stockholders' Equity 46,140,339 25,535,660 Total Liabilities and Stockholders' Equity $ 84,368,878 $ 47,734,895 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 4,925,001 4,240,451 General and administrative 8,148,929 5,915,290 Stock-based compensation – general and administrative 7,498,817 1,965,500 Total Operating Expenses 20,572,747 12,121,241 Loss before Income Taxes (20,572,747) (12,121,241) Income tax expense 576,000 576,000 Net Loss $ (21,148,747) $ (12,697,241) Net Loss Per Share – Basic and Diluted $ (0.31) $ (0.19) Weighted Average Common Shares Outstanding – Basic and Diluted 68,053,607 67,500,000 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (21,148,747) $ (12,697,241) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 7,498,817 1,965,500 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (1,100,000) (5,044,713) Accounts payable 2,422,577 1,196,734 Accrued expenses (259,071) (801,754) Due to related party 14,270,648 14,805,474 Net Cash Provided By Operating Activities 126,353 - Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Cash contributed by parent 3,827,944 - Merger, net (2,754,296) - Proceeds from issuance of note payable to related party 3,800,111 - Net Cash Provided By Financing Activities 4,873,759 - Net Change in Cash and Cash Equivalents 112 - Cash and Cash Equivalents – Beginning of Year - - Cash and Cash Equivalents – End of Year $ 112 $ - Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $
Seattle Seahawks receiver is DK Metcalf is just fine when he doesn’t have the the ball because it means he gets to showcase his blocking skills. “I just look at it as a sign of respect that I’ve gained from other defensive coordinators and just continue to do my job with it as blocking or being a decoy,” the two-time Pro Bowler said. While opposing defenses have keyed in on Metcalf, other aspects of Seattle’s offense have surfaced during its four-game winning streak. The run has the Seahawks (8-5) sitting atop the NFC West heading into Sunday night’s game against the visiting Green Bay Packers (9-4). Geno Smith’s new top target is second-year receiver Jaxon Smith-Njigba, who needs 89 receiving yards for his first career 1,000-yard season. Smith-Njigba has 75 catches for 911 yards and five touchdowns, while Metcalf, often dealing with double coverage, has 54 catches for 812 yards and two scores. Metcalf says he feels the pride of a “proud parent or a big brother” when it comes to Smith-Njigba’s success. Seattle’s offense also got a boost from the ground game in a 30-18 victory over the Arizona Cardinals last weekend . Zach Charbonnet, filling in for the injured Kenneth Walker III, ran for a career-best 134 yards and two touchdowns. RELATED COVERAGE 49ers LB De’Vondre Campbell refuses to enter game after losing his starting spot The Rams get 4 field goals to beat the 49ers 12-6 in a sloppy game Saints choose Jake Haener to start in Derek Carr’s place against Washington, AP source says The Seahawks face another hot team in the Packers (9-4), who have won seven of nine. Green Bay’s two losses over that stretch have come against NFC-best Detroit (12-1), including a 34-31 victory by the Lions on Dec. 5, which means the NFC North title is likely out of reach for the Packers. The Packers are well-positioned for a playoff berth, but that almost certainly won’t come this weekend. They would need a win, a loss or tie by the Atlanta Falcons and a tie between the Los Angeles Rams and San Francisco 49ers. The AP Top 25 college football poll is back every week throughout the season! Get the poll delivered straight to your inbox with AP Top 25 Poll Alerts. Sign up here . Metcalf, who learned to block from his father, former Chicago Bears offensive lineman Terrence Metcalf, says he tries to take blocking seriously to set himself apart from other receivers. His priorities are simple when he’s getting double-teamed and the ball goes elsewhere. “Trying to block my (butt) off and trying to get pancakes on defensive backs,” he said. Love heats up When the Packers surged their way into the playoffs last season, quarterback Jordan Love was a major reason why. He had 18 touchdown passes and one interception during Green Bay’s final eight games. During the last four games of this season, Love ranks third in the NFL with a 118.9 passer rating with six touchdowns, one interception and a league-best 10.3 yards per attempt. “I always feel like I can put the ball where I want to — and that’s part of it, too, having that confidence to be able to throw those passes,” Love said. “There’s always like I said a handful of plays that might not come off or be in the exact spot that you wanted it to or the throw might be a little bit off. So, that’s where you’ve just got to try to be at your best every play, be consistent and accurate as possible.” Passing fancy Green Bay’s pass defense has been picked apart the last two weeks. First, it was torched by Tua Tagovailoa and the Dolphins in a Packers win. Next, it allowed Jared Goff to complete his final 13 passes as the Lions rallied to victory. It won’t get any easier this week. Smith is second in the NFL in attempts, completions and passing yards and is fifth in completion percentage. “It’s been a remarkable turnaround for him in terms of just where he started,” Packers coach Matt LaFleur said. “It’s not always where you start, but where you finish. And it tells me a lot about the person in terms of his resiliency and ability to fight through some adversity. He’s a dangerous quarterback.” The potential return of former All-Pro cornerback Jaire Alexander (knee) could help the Packers. Fashion forward Will the Packers break out their head-to-toe white uniforms? The last time Green Bay wore the winter white look was in a 24-22 win over Houston in October. The Packers asked fans to weigh in on social media . As for the Seahawks, they’ll be sporting their “Action Green” uniforms. Metcalf is a fan. “I would say this about the Action Green, I love them personally in my opinion, but the big guys hate them. I don’t know why, don’t ask me,” he said. “Hopefully, the Packers wear all white, so it’ll be a fun-looking game.” ___ AP NFL: https://apnews.com/hub/nfl
Spotify has launched its 2024 Wrapped campaign, combining personalised user experiences with a multi-channel marketing push to celebrate a record-breaking year in music and podcasting. The campaign focuses on Australian artists, creative collaborations, and an experiential pop-up rave in Sydney. Eligible users can now access their personalised Wrapped experience via the Spotify mobile app, which highlights their top artists, songs, and trends of 2024. Wrapped’s marketing rollout includes Out-of-Home placements in Sydney and Melbourne, featuring local talent such as Tones and I , Angie McMahon , and Lithe . The campaign was developed with creative agency Akcelo and social content agency Jack Nimble, emphasising fan engagement and local pride. To mark the occasion, Spotify is hosting a Pop-Up Rave today at Parramatta Square in Sydney. Open to the public, the event features performances from ODDMOB , Young Franco , Sycco , Mistah Cee , and Talisha , celebrating the rise of dance music and rave culture in 2024. Spotify head of marketing (ANZ), Rosie Rothery , said: “2024 Spotify Wrapped is all about celebrating the Australian fans, artists, and creators who made this year the record-breaking, culture-making, fandom-shaking year it was. On the tenth anniversary of Wrapped as we know it today, we want this to be our most iconic Wrapped yet. “This year, we took our approach to the next level with an extended tease phase across Out of Home and Social, designed to ignite excitement among Australia’s Wrapped-loving public and build anticipation ahead of the launch. We dialed up the intrigue further by unveiling a mysterious Wrapped shipping container in Parramatta Square yesterday. Today, we’re thrilled to reveal its purpose—leaning into the explosion of dance music, and rave culture in 2024, we’re launching Wrapped with a pop-up rave featuring some of Australia’s most exciting DJs.” Here’s what Australia streamed most this year: Music (Australia) Podcasts (Australia) Australia’s Top Local Artists: 1. The Wiggles 2. The Kid LAROI 3. AC/DC 4. Vance Joy 5. RÜFÜS DU SOL Australia Top Local Songs: 1. “Riptide” by Vance Joy 2. “Stumblin’ In” by CYRIL 3. “Saving Up” by Dom Dolla 4. “NIGHTS LIKE THIS” by The Kid LAROI 5. “You Shook Me All Night Long” by AC/DC
D S Simon Media conducted a nationwide media tour in conjunction with U.S. Chamber of Commerce Foundation discussing Civics in Action: Students Compete for National Civics Bee Title in Washington. NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- On November 12 in Washington, D.C., a championship took place that wasn’t about sports, spelling, or science. It’s about something even more powerful: civics. Twenty-seven students, representing the hopes and futures of every American, came together in the nation’s capital for the U.S. Chamber of Commerce Foundation's National Civics Bee Championship. These young champions have proven themselves through intense local and state competitions, and now they’ll showcase the civics knowledge and skills that make democracy work. They competed not just for a trophy, but for the title of America’s National Civics Bee Champion. More than one third of U.S. adults cannot name the three branches of government, and 79% of eighth graders score below proficient in civics. The competition aimed to inspire a new generation to be civically engaged and active in shaping the future of our communities and our nation. To date, more than 8,000 students from 110 communities across 28 states have participated, with plans to reach all 50 states by 2026. For more information, visit https://nationalcivicsbee.com/ About YourUpdateTV: YourUpdateTV is a property of D S Simon Media. The video included and release was part of a media tour that was produced by D S Simon Media on behalf of U.S. Chamber of Commerce Foundation. Dante Muccigrosso Director of Media Integration & Client Reporting E: dantem@dssimon.com C: 973.524.0104 A video accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/1b7552dd-af3c-4576-bc71-98576dbba351NoneChhattisgarh: Tiger relocated successfully after 8-months operation
Israel kills at least 66 Palestinians in Gaza: medics